67 results
6-K
EX-99.1
IPHA
Innate Pharma
21 Mar 24
Innate Pharma reports Full Year 2023 Financial Results and Business Update
6:01am
for combination strategy in this clinical indication.
The Phase 2 KILT (anti-KIR in T Cell Lymphoma) trial, an investigator-sponsored, randomized trial led
6-K
EX-99.01
IPHA
Innate Pharma
6 Mar 24
Current report (foreign)
6:00am
enhance their effector functions against cancer cells. Thanks to this novel format, IPH6501 represents a promising alternative strategy to T cell
424B5
o3qfri7xjizjvw hz3v8
6 Feb 24
Prospectus supplement for primary offering
5:00pm
6-K
gv6jj bs2v
5 Jan 24
Innate Pharma S.a. 6-K
6:09am
6-K
EX-99.1
b1sh3n ps5
4 Jan 24
Innate Pharma 6-K
6:00am
F-3
xkgu 2jxcdzm00qs7o
20 Dec 23
Shelf registration (foreign)
4:45pm
6-K
uimvg3eqvvwkt3hqx
20 Dec 23
Current report (foreign)
4:30pm
6-K
EX-99.1
1izab 6dfa4nm7vqc
14 Nov 23
Innate Pharma S.a. 6-K
6:00am
6-K
EX-99.1
gs6l1nrw
7 Nov 23
Innate Pharma S.a. 6-K
6:01am
6-K
EX-99.2
nbrfm34is4oea5
14 Sep 23
Innate Pharma Reports First Half 2023 Financial Results and Business Update
6:27am
6-K
EX-99.1
xguchx7i4c60ob32
14 Sep 23
Innate Pharma Reports First Half 2023 Financial Results and Business Update
6:27am
6-K
EX-99.1
9cwl00d
14 Sep 23
Innate Pharma S.a. 6-K
6:00am
6-K
EX-99.1
oqq5uj72cvz3
12 Jun 23
Innate Pharma S.a. 6-K
6:00am
6-K
EX-99.1
4dae 5gcm
3 May 23
Innate Pharma S.a. 6-K
6:01am
424B5
bwo2zwvbq2nx d5ay04
26 Apr 23
Prospectus supplement for primary offering
4:01pm
20-F/A
EX-4.9
k14yxc6ml2qpcwno oy
20 Apr 23
Annual report (foreign) (amended)
8:47am